Last reviewed · How we verify
Pixantrone + Rituximab
Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells.
Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | Pixantrone + Rituximab |
|---|---|
| Sponsor | CTI BioPharma |
| Drug class | Topoisomerase II inhibitor + monoclonal antibody combination |
| Target | Topoisomerase II (pixantrone); CD20 (rituximab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pixantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Rituximab binds CD20 on B-cell lymphomas, triggering antibody-dependent cellular cytotoxicity and direct cell death. Together, they provide dual mechanisms targeting lymphoid malignancies.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Infection
- Cardiotoxicity
Key clinical trials
- Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (PHASE2)
- A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (PHASE2)
- Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study (PHASE1, PHASE2)
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PHASE3)
- Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (PHASE3)
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL (PHASE3)
- IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma (PHASE1)
- BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pixantrone + Rituximab CI brief — competitive landscape report
- Pixantrone + Rituximab updates RSS · CI watch RSS
- CTI BioPharma portfolio CI